NIDA Substance Abuse & HCV Conference

Conference Reports for NATAP


NIDA Substance Abuse & HCV Conference Washington, DC Nov 11-13, 2003

	NM 283 new HCV Inhibitor - (01/26/04) Adefovir Efficacy and Resistance - (01/26/04) Combination Interferon Therapy: Infergen plus Actimmune - (01/26/04) Differences between Hepatitis B and C in the Prediction of Success of Treatment Using Early Viral Kinetics - (01/26/04) Clinical Development of Entecavir for the Treatment of Chronic Hepatitis B - (01/26/04) L-Thymidine (LdT) and Related Compounds - (01/26/04) A 12 Week Randomized Placebo-Controlled Double Blind Trial of Clevudine in Patients with Chronic Hepatitis B with Post-Treatment Follow-up for 24 weeks - (01/26/04)